Marshall Urist - 11 Feb 2026 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
EVP, Research & Investments
Signature
/s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist
Issuer symbol
RPRX
Transactions as of
11 Feb 2026
Net transactions value
$0
Form type
4
Filing time
13 Feb 2026, 16:02:26 UTC
Previous filing
02 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Urist Marshall EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK /s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist 13 Feb 2026 0001838139

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Award $0 +19,970 +270% $0.000000 27,368 11 Feb 2026 Direct F1
holding RPRX Class A Ordinary Shares 19,020 11 Feb 2026 By IRA
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.